Galmed Pharmaceu (GLMD) Stock News

Galmed Pharmaceuticals (Nasdaq: GLMD) reported third quarter 2025 results and a business update on Nov 26, 2025. Cash and marketable securities totaled ~$19.2M as of Sept 30, 2025. Net loss for Q3 2025 was $1.9M (‑$0.33 per share). R&D expense rose to $1.1M in Q3 2025, while G&A declined to $1.0M. Weighted average shares expanded to 5.46M for Q3 2025 from 829,500 a year earlier.

Clinical updates: top-line AM-001 Phase 1 bioavailability results were reported Nov 18, 2025, and a Nov 17, 2025 joint VCU study showed a 3‑drug combination (Aramchol, Stivarga, Metformin) significantly enhanced GI tumor cell killing in vivo and in vitro. The company raised ~$9.3M in 2025 via equity lines and ATM.

Galmed (Nasdaq: GLMD) reported top-line results from the AM-001 Phase 1 bioavailability study of Aramchol meglumine on November 18, 2025. In 30 healthy volunteers, the study found that Aramchol meglumine granules delivered approximately 5-fold (400 mg) and 3-fold (200 mg) greater bioavailability versus Aramchol free acid 300 mg tablets.

Galmed said the unexpected PK profile supports a once-daily 400 mg regimen for upcoming oncology Phase 2 studies planned for H1 2026, may improve long-term adherence, and could reduce drug cost of goods by ~50%. The company noted prior clinical exposure including 661 patients across six trials (up to Phase 3) and 82 healthy subjects dosed with Aramchol meglumine under a UK CTA.

Galmed (NASDAQ: GLMD) reported top-line preclinical results showing a 3‑drug combination of Aramchol, Stivarga® (regorafenib) and metformin produced a synergistic anti-tumor effect in GI cancer models both in vitro and in vivo. Galmed said Aramchol enhanced regorafenib-induced autolysosome formation, activated ATM/AMPK and inactivated mTORC1/2 pathways. New patent applications (US 63/786,370 and US 63/915,832) were filed and a Phase 1b trial combining Aramchol and regorafenib, with an expansion cohort including metformin, is planned to start early 2026 at VCU Massey. Galmed noted regorafenib patent expiries in Europe Aug 2028 and U.S. July 2032 and cited regorafenib sales of €458m in the first nine months of 2022.

Galmed Pharmaceuticals (Nasdaq: GLMD), a clinical-stage biopharmaceutical company, reported Q2 2025 financial results and significant strategic shifts. The company announced a new digital asset management strategy that could allocate up to 50% ($10 million) of cash reserves to crypto investments. Additionally, Galmed modified its agreement with Entomus s.r.o., reducing its role in the SEDDS formulation project to a potential 20% stake investment of up to $2 million.

Financial highlights include cash and equivalents of $20.7 million as of June 30, 2025, compared to $15.4 million at end-2024. The company reported a net loss of $2.5 million ($0.63 per share) in Q2 2025, versus $1.1 million loss in Q2 2024. R&D expenses increased to $1.1 million, up from $0.5 million year-over-year.

Galmed Pharmaceuticals (NASDAQ: GLMD) has announced a significant shift in its treasury management strategy, planning to invest up to $10 million (approximately 50% of its current cash reserves) in digital assets. The company's board has established a dedicated Crypto Committee to oversee crypto-related activities and is engaging Tectona Ltd. as its crypto treasury management advisor.

Additionally, shareholders approved an amendment to increase the company's authorized share capital from 50 million to 900 million ordinary shares. The new strategy aims to diversify Galmed's balance sheet through blockchain-based assets, including covered call options, staking, lending, and yield-generating protocols.

Galmed Pharmaceuticals (NASDAQ: GLMD) has discovered a proprietary pharmacodynamic biomarker signature for its lead drug candidate Aramchol through analysis of Phase 3 ARMOR study data. The newly identified 70-protein signature demonstrates Aramchol's potential beyond liver diseases, particularly in cardiometabolic and inflammatory conditions.

Key findings include significant reductions in systemic inflammation, cardiac stress, and atherosclerotic drivers. Notably, the study revealed a decrease in Atrial Natriuretic Peptide (ANP), a heart failure marker, and upregulation of KDM4C, an enzyme linked to liver fibrosis suppression. The discovery was made in collaboration with Proteas Health using advanced proteomics and AI technology.

This breakthrough positions Galmed to expand Aramchol's applications into multi-billion-dollar markets beyond MASH/NASH, while providing a unique companion diagnostic tool for enhanced clinical decision-making and potential strategic partnerships.

Galmed Pharmaceuticals (NASDAQ: GLMD) reported its Q1 2025 financial results with several key developments. The company's net loss decreased to $1.1 million ($0.62 per share) compared to $1.3 million ($2.76 per share) in Q1 2024. Cash position strengthened to $20.1 million after raising $6.5 million since the start of 2025. Research and development expenses remained stable at $0.6 million, while general and administrative expenses decreased to $0.6 million from $0.8 million. Notable developments include promising results in oncology studies showing Aramchol enhancing Bayer's Regorafenib effect in GI cancer models, and signing a term sheet for developing a novel Semaglutide sublingual formulation. The company is actively diversifying its pipeline beyond liver disease into cardiometabolic and oncological indications.

Galmed Pharmaceuticals (NASDAQ: GLMD) announced significant results for Aramchol, their SCD1 inhibitor drug, in pre-clinical models of primary sclerosing cholangitis (PSC). The study showed Aramchol both prevented and reduced biliary fibrosis in PSC mouse models, with a 2-fold significant inhibition (p0.05)20% lifetime risk of developing cholangiocarcinoma (CCA), the second-most prevalent liver malignancy. Building on previous successful clinical trials showing improvement in liver fibrosis, including the ARREST Phase IIb trial and ARMOR Phase III study, Galmed plans to advance Aramchol towards Phase 2/3 clinical studies focusing on GI oncology indications.

Galmed Pharmaceuticals (NASDAQ: GLMD) has announced breakthrough results from oncology studies conducted at Virginia Commonwealth University, showing that Aramchol significantly enhances the effectiveness of Bayer's Regorafenib in treating GI cancers. The combination therapy demonstrated significant reduction in hepatic tumor growth in mice models through increased autophagy and death receptor signaling. The company plans to initiate a Phase 1b study at VCU's Massey Cancer Center in Q4 2025, testing the combination in patients with advanced GI cancers. The research revealed that Aramchol, a potent SCD1 inhibitor, interacted effectively with multiple kinase inhibitors, with Regorafenib showing the strongest results. The combination works by enhancing autophagy through distinct mechanisms, potentially offering a cost-effective first-line treatment for HCC and other liver and colorectal cancers.